USANA Health Sciences (NYSE:USNA) Announces Earnings Results, Beats Estimates By $0.07 EPS

USANA Health Sciences (NYSE:USNA - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported $0.56 EPS for the quarter, beating analysts' consensus estimates of $0.49 by $0.07, Yahoo Finance reports. The business had revenue of $200.22 million during the quarter, compared to the consensus estimate of $208.45 million. USANA Health Sciences had a return on equity of 11.13% and a net margin of 6.29%. During the same quarter in the previous year, the firm earned $0.59 earnings per share. USANA Health Sciences updated its FY 2024 guidance to 2.450-2.450 EPS.

USANA Health Sciences Stock Up 6.1 %

USNA traded up $2.10 during trading on Wednesday, reaching $36.58. 158,106 shares of the stock traded hands, compared to its average volume of 80,305. The stock has a market capitalization of $696.89 million, a PE ratio of 11.31, a P/E/G ratio of 1.20 and a beta of 0.89. The stock's 50-day moving average is $38.02 and its 200 day moving average is $42.59. USANA Health Sciences has a 12 month low of $34.15 and a 12 month high of $55.45.

Insider Transactions at USANA Health Sciences

In other news, insider Paul A. Jones sold 6,266 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total transaction of $240,489.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, insider Paul A. Jones sold 6,266 shares of the firm's stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total value of $240,489.08. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director John Turman Fleming sold 1,000 shares of the firm's stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $44.43, for a total transaction of $44,430.00. Following the completion of the transaction, the director now directly owns 2,503 shares in the company, valued at approximately $111,208.29. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 7,940 shares of company stock valued at $311,670 in the last 90 days. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. StockNews.com downgraded shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a report on Wednesday, July 24th. DA Davidson lowered their price target on shares of USANA Health Sciences from $38.00 to $35.00 and set a "neutral" rating for the company in a report on Wednesday.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.